Synapse - Nursing

Results (11)

Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas

Meeting Abstract

Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Meeting Abstract

Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Hypertension (HTN) in patients (pts) treated with ibrutinib (IBR) for chronic lymphocytic leukemia (CLL)

Meeting Abstract

Sarraf Yazdy, M.; Roeker, L.; Gashonia, L.; Goodfriend, J.; Narkhede, M.; Rhodes, J.; Kennard, K.; Morse, H.; Dorsey, C.; Battiato, K.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation

Meeting Abstract

Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation

Meeting Abstract

Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; more...
Hematological Oncology (2019)

Fulltext@MSK | Save

A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma

Meeting Abstract

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save